Clinical trial · Interventional
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
Pilot Study to Evaluate the Effect of Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
NCT03394105CI-TRIAL-00037514completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this trial, the effect of intrapleural docetaxel administration using medical pleuroscopywill be evaluated in Lung Cancer patient with malignant effusion.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Carcinoma | Non-Small Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Pleural Effusion, Malignant | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intrapleural docetaxel administration | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- intrapleural docetaxel administration
- description
- Docetaxel will be administed to interpleural space using medical pleuroscopy in malignant effusion with lung cancer.
- interventionNames
- Drug: intrapleural docetaxel administration
Primary outcomes (2)
- measure
- Overall respose rate(ORR)
- timeFrame
- through study completion (2.5 years)
- description
- Rate of CR and PR
- measure
- Complete resonse (CR) rate
- timeFrame
- through study completion (2.5 years)
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 20, and NSCLC patients with malignant pleural effusion and related symptoms * ECOG ≤ 2 * Blood test ANC≥ 1500/mm3, Hb ≥ 8.0g/dl, platelet count ≥ 100000/mm3 Serum creatinine ≤ 1.8mg/dl, Total bilirubin within normal limits, Transaminases ≤ 1.5 x UNL, Alkaline phosphatase ≤ 2.5 X UNL BUN ≤ 25mg/dl, Creatinine clearance ≥ 50ml/min * Negative serum or urine pregnancy test for women for childbearing age * Patients who provide written informed consent for the study Exclusion Criteria: * Age \< 20 * Patients who were previously perfomed pleurodesis * Patients who were previously treated with thoracic radiosurgery * Patinet with bilateral pleural effusion * Age ≥ 80yrs * Patients with histories of hypersensitivity to Docetaxel * Patients with cardiovascular, respiratory, hepatic, renal, gastrointestinal, neunological disease, asthma, MI, stroke, arrhythmia, uncontrolled hypertionsion, etc. that would effect absorption, distribution, and metabolism of IP or be risk factors during IP administrion. * Patients who could not understand the study procedure
References
Publications (0)
Data not yet available
No reference posted for this study.